BioPharma Credit PLC Dividend Declaration (0484Y)
16 August 2018 - 9:45PM
UK Regulatory
TIDMBPCR
RNS Number : 0484Y
BioPharma Credit PLC
16 August 2018
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ended 30 June 2018 of $0.0175 per ordinary
share, payable on 28 September 2018 to ordinary shareholders on the
register as at 31 August 2018. Shareholders in receipt of such a
dividend will be treated for UK tax purposes as though they have
received a payment of interest. This will result in a reduction in
the corporation tax payable by the Company.
The Company is currently paying and continues to target a 7 per
cent annual dividend yield per ordinary share (calculated by
reference to the IPO issue price) for the remainder of 2018,
excluding the potential impact of C Share conversions.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 31 August 2018 (the
"Election Date").
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Asset Services, The
Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU when
completed, will be available on the Group's website shortly at
www.bpcruk.com/investor-materials. CREST shareholders must elect
via CREST.
LEI: 213800AV55PYXAS7SY24
-Ends-
Link Company Matters Limited
Company Secretary
16 August 2018
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DIVPFMBTMBBBBIP
(END) Dow Jones Newswires
August 16, 2018 07:45 ET (11:45 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2023 to May 2024